Revive Therapeutics Ltd (RVVTF)

[Fastlane2]

The IRB giving Revive the green light for compassionate use is some news that we can be expecting shortly as well.

IRB OK's Revive Therapeutics' compassionate use of Bucillamine in COVID-19
Sep. 16, 2020 9:10 AM ET Revive Therapeutics Ltd. (RVVTF)By: Mamta Mayani, SA News Editor14 Comments
Revive Therapeutics' (OTCPK:RVVTF) expanded access protocol (EAP) for compassionate use of Bucillamine in the treatment of COVID-19 received approval from the independent Institutional Review Board (IRB).
The EAP is being done to complement the Company’s Phase 3 COVID-19 study in the U.S. Revive expects patient enrollment in U.S. this month.
The objective is to monitor the safety and efficacy of Bucillamine (600 mg/day) and any clinical symptoms when administered up to 14 days in hospitalized patients with severe COVID-19. 14 and 42 days follow up assessment will be done after treatment completion.
The EAP for compassionate use provides physicians with access to Bucillamine under existing IND application for COVID-19.